OBJECTIVE： To evaluate therapeutic efficacy of Shengxuening tablets in the treatment of iron-deficiency anemia during pregnancy， so as to provide evidence for clinical decisions. METHODS： Retrieved from CNKI， Wanfang， VIP and PubMed， clinical randomized controlled trials （RCTs） about Shengxuening tablets in the treatment of iron-deficiency anemia during pregnancy were collected during 2008-2018. After screening literatures and extracted information， the literature quality was evaluated by using improved Jadad scale. Meta-analyses was performed by using Stata 12.0 software. RESULTS： A total of 11 RCTs were included， inulving 1 617 patients. Total response rate of Shengxuening tablets was significantly higher than those of ferrous sulfate [OR＝8.73，95％CI（2.964，25.69），P＜0.05]， ferrous succinate [OR＝1.86，95％CI（1.04，3.33），P＜0.05] and dietory conditioning [OR＝3.43，95％CI（2.08，5.66），P＜0.05]， with statistical significance. CONCLUSIONS： Therapeutic efficacy of Shengxuening tablets is significantly better than that of routine iron supplements in the treatment of iron-deficiency anemia during pregnancy.